Equities Analysts Issue Forecasts for USANA Health Sciences, Inc.’s Q3 2019 Earnings (NYSE:USNA)

USANA Health Sciences, Inc. (NYSE:USNA) – Jefferies Financial Group issued their Q3 2019 earnings estimates for USANA Health Sciences in a note issued to investors on Thursday, August 22nd. Jefferies Financial Group analyst S. Wissink forecasts that the company will earn $0.84 per share for the quarter. Jefferies Financial Group currently has a “Hold” rating and a $65.00 target price on the stock. Jefferies Financial Group also issued estimates for USANA Health Sciences’ Q4 2019 earnings at $1.02 EPS, FY2019 earnings at $3.78 EPS, Q1 2020 earnings at $0.88 EPS, Q2 2020 earnings at $1.03 EPS, Q3 2020 earnings at $1.02 EPS, Q4 2020 earnings at $1.44 EPS and FY2020 earnings at $4.38 EPS.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, July 23rd. The company reported $0.91 EPS for the quarter, missing the Zacks’ consensus estimate of $0.93 by ($0.02). USANA Health Sciences had a return on equity of 27.22% and a net margin of 9.68%. The company had revenue of $256.00 million for the quarter, compared to analyst estimates of $254.66 million. During the same period in the prior year, the firm posted $1.36 earnings per share. The business’s quarterly revenue was down 15.1% compared to the same quarter last year.

USNA has been the subject of a number of other reports. Sidoti downgraded USANA Health Sciences from a “buy” rating to a “neutral” rating and set a $70.00 price objective for the company. in a research report on Wednesday, July 3rd. Pivotal Research reaffirmed a “buy” rating on shares of USANA Health Sciences in a report on Wednesday, July 24th. TheStreet downgraded USANA Health Sciences from a “b-” rating to a “c+” rating in a report on Thursday, July 11th. Finally, ValuEngine raised USANA Health Sciences from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $70.00.

Shares of USANA Health Sciences stock opened at $64.29 on Monday. USANA Health Sciences has a one year low of $58.30 and a one year high of $134.65. The company has a market cap of $1.48 billion, a PE ratio of 12.46 and a beta of 0.44. The business has a 50-day simple moving average of $64.96 and a 200-day simple moving average of $80.58.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Verition Fund Management LLC acquired a new stake in USANA Health Sciences in the 2nd quarter worth about $220,000. Nuveen Asset Management LLC purchased a new position in shares of USANA Health Sciences in the 2nd quarter worth about $17,458,000. UBS Asset Management Americas Inc. raised its holdings in shares of USANA Health Sciences by 19.9% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 9,172 shares of the company’s stock worth $729,000 after purchasing an additional 1,521 shares during the period. D. E. Shaw & Co. Inc. raised its holdings in shares of USANA Health Sciences by 13.1% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 271,443 shares of the company’s stock worth $21,560,000 after purchasing an additional 31,396 shares during the period. Finally, Morgan Stanley raised its holdings in shares of USANA Health Sciences by 0.3% in the 2nd quarter. Morgan Stanley now owns 297,254 shares of the company’s stock worth $23,611,000 after purchasing an additional 773 shares during the period. 66.39% of the stock is owned by hedge funds and other institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.